Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Heron Therapeutics, Inc.

LOS ANGELES–(BUSINESS WIRE)–$HRTX #CLASSACTIONGlancy
Prongay & Murray LLP
(“GPM”) reminds investors of the upcoming August
5, 2019 
deadline to file a lead plaintiff motion in the class
action filed on behalf of Heron Therapeutics, Inc. (“Heron Therapeutics”
or the “Company”) (NASDAQ: HRTX)
investors who purchased securities between October 31, 2018 and
April 30, 2019
, inclusive (the “Class Period”).

If you are a shareholder who suffered a loss, click here to
participate.

If you wish to learn more about this action, or if you have any
questions concerning this announcement or your rights or interests with
respect to these matters, please contact Lesley Portnoy, Esquire, at
310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com,
or visit our website at www.glancylaw.com.

On May 1, 2019, the Company confirmed receipt of a Complete Response
Letter from the FDA in which the FDA was unable to approve the Company’s
New Drug Application for a new postoperative pain medication it had been
developing, due to the need for additional information.

On this news, shares of Heron Therapeutics fell $3.93 per share, or over
18%, to close at $17.75 on May 1, 2019, thereby injuring investors.

The complaint filed in this class action alleges that throughout the
Class Period, Defendants made materially false and/or misleading
statements, as well as failed to disclose material adverse facts about
the Company’s business, operations, and prospects. Specifically,
Defendants failed to disclose to investors: (1) the Company had failed
to include adequate Chemistry, Manufacturing, and Controls and
non-clinical information in its New Drug Application (“NDA”) with the
U.S. Food and Drug Administration (“FDA”) for HTX-011; (2) the foregoing
increased the likelihood that the FDA would not approve the Company’s
NDA for HTX-011; and (3) as a result, defendants’ public statements were
materially false and/or misleading at all relevant times.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased or otherwise acquired Heron Therapeutics securities
during the Class Period you may move the Court no later than August
5, 2019
to request appointment as lead plaintiff in this putative
class action lawsuit. To be a member of the class action you need not
take any action at this time; you may retain counsel of your choice or
take no action and remain an absent member of the class action. If you
wish to learn more about this class action, or if you have any questions
concerning this announcement or your rights or interests with respect to
the pending class action lawsuit, please contact Lesley Portnoy,
Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles,
California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com,
or visit our website at www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Lesley Portnoy,
310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com